Publication details
Substituční imunoglobulinová léčba
| Title in English | Immunoglobulin repalcement therapy |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Patients with agammaglobulinaemia and hypogammaglobulinaemia require immunoglobulin G (IgG) replacement therapy. The most common routes of administration of IgG replacement therapy are intravenous (IVIG) or subcutaneous (SCIG). The success of immunoglobulin prophylaxis via the intravenous route depends predominantly on maintaining an adequate protection against infections. According to international guidelines the immunoglobulin monthly dose of 300 - 600 mg/kg body weight should be administered intravenously every 3 or 4 weeks and subcutaneously once/twice a week. The anti-IgA antibody test identifies the patients with the risk of anaphylactoid reactions in IVIG replacement. The SCIG delivery may be used in patients with anti-IgA antibodies and previous systemic reactions to IVIG. The home therapy may improve the quality of life in patients who require lifelong IgG replacement. |